The impact of adequate psychopharmacotherapy on the efficiency of treatment in patients with rheumatoid arthritis
Абрамкин А. А., Лисицyна Т. А., Велтишчев Д. Y., Серавина О. Ф., Ковалевскайа О. Б., Насонов Е. Л.
Научно-практическая ревматология
Т. 56, Вып. 2, С. 173-183
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.14412/1995-4484-2018-173-183
Аннотация:
Mental disorders (MDS) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) substantially deteriorate the course and efficiency of therapy for rheumatoid arthritis (RA). There have been practically no studies on the impact of psychopharmacotherapy (PPT) for MDS on the efficacy of standard disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs). Objective: to investigate the impact of adequate PPT for MDS of ADS on the efficacy of DMARDs and BAs in patients with RA. Subjects and methods. The investigation included 128 patients (13[%] men and 87[%] women) with documented RA in accordance with the 1987 American College of Rheumatology (ACR) criteria. The patients' mean age was 47.4}0.9 years; the median duration of RA was 96 [48; 228] months. DAS28 averaged 5.34}0.17. 75.1[%] of the patients received DMARDs. The diagnosis of MDS was based on the ICD-10 codes, by applying a semi-structured interview and the Hospital Anxiety and Depression Scale. Changes in th
Ключевые слова:
Biological agents; Disease-modifying antirheumatic drugs; Efficiency of therapy; Mental disorders; Psychopharmacotherapy; Remission; Rheumatoid arthritis; Therapy adherence.
Язык текста: Русский
ISSN: 1995-4492
Абрамкин А. А.
Лисицyна Т. А.
Велтишчев Д. Y. Д.Ю.
Серавина О. Ф.
Ковалевскайа О. Б.
Насонов Е. Л. Евгений Львович 1948-
Abramkin A. A.
Lisitsyna T. A.
Veltishchev D. Y. D.Yu.
Seravina O. F.
Kovalevskaya O. B.
Nasonov E. L. Evgenij L`vovich 1948-
The impact of adequate psychopharmacotherapy on the efficiency of treatment in patients with rheumatoid arthritis
Текст визуальный непосредственный
Научно-практическая ревматология
ИМА-Пресс
Т. 56, Вып. 2 С. 173-183
2018
Статья
Biological agents Disease-modifying antirheumatic drugs Efficiency of therapy Mental disorders Psychopharmacotherapy Remission Rheumatoid arthritis Therapy adherence.
Mental disorders (MDS) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) substantially deteriorate the course and efficiency of therapy for rheumatoid arthritis (RA). There have been practically no studies on the impact of psychopharmacotherapy (PPT) for MDS on the efficacy of standard disease-modifying antirheumatic drugs (DMARDs) and biological agents (BAs). Objective: to investigate the impact of adequate PPT for MDS of ADS on the efficacy of DMARDs and BAs in patients with RA. Subjects and methods. The investigation included 128 patients (13[%] men and 87[%] women) with documented RA in accordance with the 1987 American College of Rheumatology (ACR) criteria. The patients' mean age was 47.4}0.9 years; the median duration of RA was 96 [48; 228] months. DAS28 averaged 5.34}0.17. 75.1[%] of the patients received DMARDs. The diagnosis of MDS was based on the ICD-10 codes, by applying a semi-structured interview and the Hospital Anxiety and Depression Scale. Changes in th